Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors

What Was Tested

The trial (phase 4) is built around Semaglutide.

It had two arms (groups): Arm I (LM) (active comparator) and Arm II (LM+Sema) (experimental).

The registry classes the interventions as behavioral, drug, other and procedure.

Who Took Part

Enrollment: 50 planned participants were the target.

It was open to women only aged from 46 years up to 55 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Breast cancer diagnosed after menopause (menopause defined as the natural/spontaneous cessation of menses for at least 12 months). Breast cancer (BC) diagnosed within the past five years. BC stage 1, 2, or 3. Aged 46-55 years. Body mass index (BMI) ≥ 30 kg/m\^².

The full record lists 7 inclusion and 20 exclusion criteria; among the exclusions: early menopause (menopause occurring before age 46); statin use; history of smoking.

How the Study Was Run

It was run as a randomized, parallel-group and single-blind study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In this single-blind Semaglutide study one party knew the assignments and the other did not.

Those kept unaware of assignments: outcomes assessor.

It started in 2026-09-01 with completion listed for 2031-07-30.

It ran at 1 site in United States.

Its stated primary purpose is supportive care.

What Was Measured

Researchers chose this as the main measure: Change in PWV between arms (Aim 1) (time frame: Baseline to 24 weeks). Change in protein expression between arms (Aim 2a) (time frame: Baseline to 24 weeks).

It also tracked 23 secondary outcomes, for example Change in AIx between arms (Aim 1), Change in RHI between arms (Aim 1), Change in PWV within arms (Aim 1), Change in AIx within arms (Aim 1), Change in RHI within arms (Aim 1) and Change in body weight between arms (Aim 1).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 50 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.